Table 4 Platinum-containing regimens for metastatic triple-negative breast cancer.
Study | Regimen | Study design and setting | Number of patients | ORR | mPFS (months) | mOS (months) |
|---|---|---|---|---|---|---|
Isakoff SJ et al.12 | Cisplatin 75 mg/m2 or Carboplatin (AUC = 6) | Phase II, first-or second-line | 86 | 25.6% | 2.9 | 11 |
Tutt A et al.13 | Carboplatin (AUC = 6), q3w | Phase III, first-line | 188 | 31.4% | 3.1 | NR |
docetaxel 100 mg/m2, q3w | 188 | 35.6% | 4.5 | NR | ||
HU XC et al.6 (our center) | Cisplatin,75 mg/m2, d1 + gemcitabine,1250 mg/m2, d1,8, q3w | Phase III, first-line | 120 | 64.0% | 7.73 | NR |
Nab-paclitaxel 175 mg/m2, d1 + gemcitabine d1,8, q3w | 120 | 49.0% | 6.47 | NR | ||
Yardley D A et al.10 | Nab-paclitaxel 125 mg/m2 + carboplatin AUC = 2, d1, 8, q3w | Phase II, first-line | 64 | 71.9% | 7.4 | 16.4 |
Nab-paclitaxel 125 mg/m2 + gemcitabine, 1000 mg/m2, day1, 8, q3w | 61 | 37.7% | 5.4 | 11.9 | ||
Gemcitabine, 1000 mg/m2 +carboplatin AUC = 2, days 1, 8, q3w | 66 | 43.9% | 6.0 | 13.7 | ||
Fan Y et al.14 | Docetaxel, 75 mg/m2 + cisplatin, 75 mg/m2, d1, q3w | Phase II, first-line | 27 | 63.0% | 10.9 | 32.8 |
Docetaxel, 75 mg/m2 + capecitabine bid 2 weeks on, 1 week off, q3w | 26 | 15.4% | 4.8 | 21.5 | ||
Zhang J et al.17 (our center) | Vinorelbine,30 mg/m2 + Oxaliplatin,90 mg/m2, biweekly, q4w | Phase II, second- or third-line | 44 | 31.6% | 4.3 | 12.6 |
Li Q et al.18 | Capecitabine,2000 mg/m2, d1–14 + cisplatin, 75 mg/m2, d1, q3w | Phase II, all lines | 33 | 63.6% | 8.2 | 17.8 |
